文献速递乳腺癌骨软组织肉瘤与黑色素瘤

INX-315,一种选择性CDK2抑制剂,在实体瘤中诱导细胞周期阻滞和衰老

INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors.
PubMed 文献 · Cancer Discov · 2024-01-01

本研究描述了一种新型高选择性CDK2抑制剂INX-315,利用细胞实验、人源肿瘤异种移植(PDX)和转基因小鼠模型,发现INX-315可促使视网膜母细胞瘤蛋白低磷酸化并诱导治疗诱导的衰老(TIS),在CCNE1扩增肿瘤中持久控制肿瘤生长;可克服乳腺癌对CDK4/6抑制剂的耐药,恢复细胞周期控制并重建CDK4/6i诱导的TIS染色质架构;通过更深度抑制E2F靶点延迟乳腺癌CDK4/6i耐药的发生。结果支持选择性CDK2抑制剂的临床开发。

要点

  • INX-315是一种新型高选择性CDK2抑制剂,对其它CDK家族成员选择性高。
  • INX-315在CCNE1扩增肿瘤中诱导视网膜母细胞瘤蛋白低磷酸化与治疗诱导的衰老,持久控制肿瘤生长。
  • INX-315可克服乳腺癌CDK4/6i耐药,并延迟CDK4/6i耐药的发生。

核心结论

  • 研究结果支持选择性CDK2抑制剂的临床开发;INX-315在CCNE1扩增癌症和CDK4/6i耐药乳腺癌的临床前研究中均显示活性,CDK2抑制诱导细胞周期阻滞和类似细胞衰老的表型,数据支持在临床试验中开发选择性CDK2抑制剂。

研究设计与样本

  • 采用基于细胞的实验、人源肿瘤异种移植(PDX)和转基因小鼠模型开展临床前研究,描述新型高选择性CDK2抑制剂INX-315。

主要发现

  • INX-315促使视网膜母细胞瘤蛋白低磷酸化并诱导治疗诱导的衰老(TIS),在CCNE1扩增肿瘤中持久控制肿瘤生长。
  • INX-315克服乳腺癌对CDK4/6i的耐药,恢复细胞周期控制,同时重建CDK4/6i诱导的TIS的染色质架构。
  • INX-315通过驱动对E2F靶点的更深抑制,延迟乳腺癌中CDK4/6i耐药的发生。

临床怎么用

  • 原文未据此给出临床推荐,仅结论指出结果支持选择性CDK2抑制剂的临床开发。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Cyclin-dependent kinase 2 (CDK2) is thought to play an important role in driving proliferation of certain cancers, including those harboring CCNE1 amplification and breast cancers that have acquired resistance to CDK4/6 inhibitors (CDK4/6i). The precise impact of pharmacologic inhibition of CDK2 is not known due to the lack of selective CDK2 inhibitors. Here we describe INX-315, a novel and potent CDK2 inhibitor with high selectivity over other CDK family members. Using cell-based assays, patient-derived xenografts (PDX), and transgenic mouse models, we show that INX-315 (i) promotes retinoblastoma protein hypophosphorylation and therapy-induced senescence (TIS) in CCNE1-amplified tumors, leading to durable control of tumor growth; (ii) overcomes breast cancer resistance to CDK4/6i, restoring cell cycle control while reinstating the chromatin architecture of CDK4/6i-induced TIS; and (iii) delays the onset of CDK4/6i resistance in breast cancer by driving deeper suppression of E2F targets. Our results support the clinical development of selective CDK2 inhibitors. SIGNIFICANCE: INX-315 is a novel, selective inhibitor of CDK2. Our preclinical studies demonstrate activity for INX-315 in both CCNE1-amplified cancers and CDK4/6i-resistant breast cancer. In each case, CDK2 inhibition induces cell cycle arrest and a phenotype resembling cellular senescence. Our data support the development of selective CDK2 inhibitors in clinical trials. See related commentary by Watts and Spencer, p. 386. This article is featured in Selected Articles from This Issue, p. 384.

来源:Cancer Discov,查看原文。版权归原作者所有。

引用

  1. Dietrich C, Trub A, Ahn A, et al. INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors. Cancer Discov. 2024. PMID: 38047585. doi:10.1158/2159-8290.CD-23-0954

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。